Showing results (41-50 of 78) with videos related to
Sort By:
Pageof 8
Thrombosis and Haemostasis|February 28, 1989
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis modelD Spriggs, H K Gold, Y Hashimoto, et al.Internal Medicine Journal|May 3, 2006
Changing attitudes to the management of ischaemic stroke between 1997 and 2004: a survey of New Zealand physiciansJ Somerfield, P A Barber, N E Anderson, et al.Seminars in Oncology|November 5, 1997
Salvage weekly paclitaxel in recurrent ovarian cancerN R Abu-Rustum, C Aghajanian, R R Barakat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1994
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancerJ H Schiller, B Storer, K Tutsch, et al.Gynecologic Oncology|March 27, 2001
Phase I trial of ifosfamide and 24-h infusional paclitaxel in pelvic malignancies: a Gynecologic Oncology Group studyM Markman, D Spriggs, R A Burger, et al.Seminars in Oncology|October 1, 1994
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factorJ H Schiller, B Storer, K Tutsch, et al.Cancer Chemotherapy and Pharmacology|January 1, 1993
Evidence of an absorption phase after short intravenous suramin infusionsP R Hutson, K Tutsch, D Spriggs, et al.Cancer Research|August 15, 1991
Tumor necrosis factor expression by human ovarian carcinoma in vivoH Takeyama, N Wakamiya, C O'Hara, et al.Cytokine & Growth Factor Reviews|April 1, 2000
Whole body hyperthermia cytokine induction: a review, and unifying hypothesis for myeloprotection in the setting of cytotoxic therapyD M Katschinski, G J Wiedemann, W Longo, et al.The Journal of Infectious Diseases|July 1, 1997
Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteersD A Sack, R B Sack, J Shimko, et al.Pageof 8